New pain block could keep lung surgery patients comfortable for days
NCT ID NCT07134660
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a long-acting painkiller (liposomal bupivacaine) to a standard one (bupivacaine hydrochloride) for numbing nerves between the ribs during lung surgery. About 210 adults having keyhole lung surgery will be randomly assigned to one of three groups: the long-acting block, the standard block, or no block. The goal is to see if the long-acting version provides better pain control from 25 to 72 hours after surgery, which could reduce opioid use and help patients recover faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal bupivacaine
What this could lead to
If it works, this could provide longer-lasting pain relief after lung surgery, reducing the need for opioids and speeding recovery.
What could go wrong
This is a mid-sized trial (210 people) and the effect may be modest. The long-acting version is more expensive, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai pulmonary hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••